Skip to content
Screener

MoonLake Immunotherapeutics MLTX Total Liabilities

Total Liabilities at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$17.76M+43.4%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$6.29M-34.4%
Alumis Inc. logo
Alumis Inc.ALMS
$104.57M+12.5%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
$14.06M+33.1%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$136.19M-14.7%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$1.52B+69.5%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.53B-54.2%
Enterprise value$1.34B-57.1%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 8:55 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001821586-26-000007
(in thousands, except share and per share data)March 31, 2026 (Unaudited)December 31, 2025
Long-term portion of operating lease liabilities865374
Pension liability353—
Total non-current liabilities100,23674,474
Total liabilities146,350119,952
Commitments and contingencies (Note 15)
Shareholders' equity
Class A Ordinary Shares: $0.0001 par value per share; 500,000,000 shares authorized; 72,134,066 shares issued and outstanding as of March 31, 2026; 71,373,579 shares issued and outstanding as of December 31, 202577
Additional paid-in capital786,313766,781

Item 1. Financial Statements (Unaudited)

FAQ

What is MoonLake Immunotherapeutics's total liabilities?
MoonLake Immunotherapeutics (MLTX) reported total liabilities of $146.35M in Q1 2026.
How has MoonLake Immunotherapeutics's total liabilities changed year-over-year?
MoonLake Immunotherapeutics's total liabilities increased by 48.3% year-over-year, from $98.68M to $146.35M.
What is the long-term trend for MoonLake Immunotherapeutics's total liabilities?
Over 5 years (2020 to 2025), MoonLake Immunotherapeutics's total liabilities has grown at a 96.0% compound annual growth rate (CAGR), from $4.15M to $119.95M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about MoonLake Immunotherapeutics's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude